Blood, Vol. 101, Issue 3, 1141-1148, February 1, 2003
Supplemental materials for: Kogan et al, Vol 101, Issue 3, 1141-1148.
Supplemental Figure:
A
B
C
Supplemental figure. C/EBPs suppress growth of murine myeloid leukemia in vivo. Bone marrow and spleen cells of leukemic mice were harvested and transduced with retroviruses expressing MIG (control), hC/EBP
, or hC/EBP
. At 24 ours after the second round of infection, GFP+ cells were sorted and intravenously injected into sublethally irradiated (4.5 Gy) healthy FVB/N females. (A) PML-RAR leukemia #1111, 50,000 cells per animal. Control mice n = 5, C/EBP mice n = 5, C/EBP mice n = 4. (B) PML-RAR leukemia #1111, 25,000 cells per animal. Control mice n = 4, C/EBP mice n = 5, C/EBP mice n = 5. (C) PML-RAR leukemia #935, 50,000 cells per animal. Control mice n = 6, C/EBPa mice n = 6, C/EBP mice n = 6. (A, B) For PML-RAR leukemia #1111 recipients of C/EBP transduced cells survived longer. This prolongation of survival approached statistical significance for C/EBP when 50,000 cells were used (A, p=.06) and was marked in recipients of 25,000 C/EBP transduced cells (B, mean increase in survival 26 days, median 23 days, p=.02). (C) Both C/EBP and C/EBP modestly prolonged the survival of mice that received PML-RAR leukemia #935 cells (C/EBP: mean increase in survival 3 days, median 3 days, P =.003; C/EBP: mean increase in survival 6 days, median 6.5 days, P =.00001).
